PAREXEL Names Maykin Ho to Board of Directors

BOSTON, Aug. 26, 2015 /PRNewswire/ -- PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that its Board of Directors have elected Maykin Ho, Ph.D., to the Board, effective August 26, 2015.

Dr. Ho is a retired partner of the Goldman Sachs Group where she served as advisory director of Global Healthcare Investment Banking, as senior biotechnology analyst, and as co-head of healthcare for Global Investment Research.  Earlier in her career, Dr. Ho held various managerial positions in licensing, strategic planning, marketing and research at DuPont-Merck Pharmaceuticals and DuPont de Nemours & Company.

"With more than 30 years of experience in the healthcare and finance industries, Dr. Ho is an excellent addition to our Company, and we welcome her to our Board of Directors," said Josef von Rickenbach, Chairman and Chief Executive Officer, PAREXEL. "As we continue to be a premier provider to the biopharmaceutical industry in the development and commercialization of new and innovative drug treatments worldwide, our clients and shareholders will benefit from Maykin's expertise, insight and perspective."

Dr. Ho is a member of the Board of Directors of the Aaron Diamond AIDS Research Center and of Agios Pharmaceuticals. She formerly served on the Investment Committee of the Society of Neuroscience, as well as the Advisory Council for the Department of Biological Chemistry and Molecular Pharmacology of the Harvard Medical School.

"PAREXEL is a leader in biopharmaceutical drug development, and I am honored to join the Board of Directors," said Dr. Ho.  "I look forward to working with the Board of Directors and the management team to help achieve the Company's operational and financial goals and advance PAREXEL's mission to make the world a healthier place."

After receiving her Ph.D. in microbiology and immunology and a B.S. in biology from the State University of New York, Downstate Medical Center, Dr. Ho was a postdoctoral fellow at Harvard Medical School.  She is also a graduate of the Advanced Management Program at Duke University's Fuqua School of Business. 

Dr. Ho's accomplishments have been recognized in the industry. Among her awards and honors, she received the 2007 Asian Women in Business Corporate Leadership Award and the 2004 National Association for Asian American Professionals Leadership Award.

About PAREXEL International
PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of expertise-based contract research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. PAREXEL Informatics provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL has offices in 80 locations in 51 countries around the world, and had approximately 18,660 employees in the fourth quarter.  For more information about PAREXEL International visit www.PAREXEL.com.

PAREXEL and PAREXEL Informatics are trademarks or registered trademarks of PAREXEL International Corporation or its affiliates.

This release contains "forward-looking" statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand.   For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements.  Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "will," "would," "could," "should,"  "targets," and similar expressions are also intended to identify forward-looking statements.  The forward-looking statements in this release involve a number of risks and uncertainties.  The Company's actual future results may differ materially from the results discussed in the forward-looking statements contained in this release.  Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from restructurings, including expense savings from the $30 – $45 million restructuring charge disclosed in the press release dated June 23, 2015; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions, and to integrate newly acquired businesses including the acquisitions of ClinIntel Limited and Quantum Solutions India, or enter into new lines of business; the impact on the Company's business of government regulation of the drug,  medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of foreign currency exchange rate fluctuations and other international economic, political, and other risks.   Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Annual Report on Form 10-K for the fiscal year ended June 30, 2015 as filed with the Securities and Exchange Commission on August 25, 2015, which "Risk Factors" discussion is incorporated by reference in this press release.  The Company specifically disclaims any obligation to update these forward-looking statements in the future.  These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.

Contacts:
Diana Martin, PAREXEL International
Tel: +1 781-434-5516
Email: [email protected]                                                                                 

Cristi Barnett, PAREXEL International
Tel.: +1 781-434-4019
Email: [email protected]

SOURCE PAREXEL International Corporation

Related Links

http://www.parexel.com